Otsuka Holdings Co., Ltd.
Stock Price Chart
2026/06/15 UpdatedPrice Trend
2026/06/15 UpdatedPrice & Trading Details
2026/06/15 UpdatedPRICE
TRADING
Analyst Recommendations 12 analysts
Updated 2026/06/05Earnings Calendar
Updated 2026/06/05Recent Earnings
| Date | EPS Est. | EPS Actual | Surprise |
|---|---|---|---|
| 2026/04/28 | ¥134.20 | ¥186.31 | +38.8% |
| 2026/02/12 | ¥74.42 | ¥124.25 | +67.0% |
| 2025/10/31 | ¥148.55 | ¥234.69 | +58.0% |
| 2025/07/31 | ¥142.83 | ¥167.55 | +17.3% |
Shareholder Composition
Updated 2026/06/05Top Mutual Funds / ETFs
Updated 2026/06/05Major Holders
Updated 2026/06/05| Fund Name | Ownership | Shares | Change |
|---|---|---|---|
|
VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund
|
7.9M | 0.00% | |
|
VANGUARD STAR FUNDS-Vanguard Total International Stock Index Fund
|
6.4M | +0.80% | |
|
VANGUARD TAX-MANAGED FUNDS-Vanguard Developed Markets Index Fund
|
4.2M | +2.00% | |
|
iShares Trust-iShares Core MSCI EAFE ETF
|
3.1M | +1.19% | |
|
iShares, Inc.-iShares MSCI Japan ETF
|
1.8M | +5.64% | |
|
Fidelity Concord Street Trust-Fidelity International Index Fund
|
1.6M | +1.22% |
| Institution | Ownership | Shares | Change |
|---|---|---|---|
|
Aristotle Capital Management, LLC
|
1.2M | -7.08% | |
|
Pacer Advisors, Inc.
|
201.5K | +7.14% | |
|
Paradigm Asset Management Company, LLC
|
20.0K | 0.00% |
Dividend History 3Years Growth
Updated 2026/06/14| Year | Dividend | Change |
|---|---|---|
| 2025 | ¥140 | +16.7% |
| 2024 | ¥120 | +9.1% |
| 2023 | ¥110 | +10.0% |
| 2022 | ¥100 | 0.0% |
| 2021 | ¥100 | - |
Financial Performance
2026/06/14 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥1,498,276M | ¥1,737,998M | ¥2,018,568M | ¥2,329,861M |
| Gross Profit | ¥1,003,245M | ¥1,168,496M | ¥1,407,348M | ¥1,669,428M |
| Operating Income | ¥152,469M | ¥186,064M | ¥291,668M | ¥415,992M |
| Pretax Income | ¥168,478M | ¥179,017M | ¥149,178M | ¥344,645M |
| Net Income | ¥125,463M | ¥133,906M | ¥121,616M | ¥343,120M |
| EPS | ¥231.15 | ¥246.78 | ¥224.10 | ¥633.76 |
| Operating Margin | 10.18% | 10.71% | 14.45% | 17.85% |
| Balance Sheet | ||||
| Total Assets | ¥2,820,915M | ¥3,102,638M | ¥3,361,244M | ¥3,739,251M |
| Total Equity | ¥2,010,994M | ¥2,225,255M | ¥2,393,683M | ¥2,733,580M |
| Total Liabilities | ¥809,921M | ¥877,383M | ¥967,561M | ¥1,005,671M |
| Cash | ¥410,684M | ¥471,634M | ¥513,341M | ¥426,173M |
| Interest-bearing Debt | ¥212,453M | ¥194,161M | ¥214,187M | ¥189,383M |
| Equity Ratio | 71.29% | 71.72% | 71.21% | 73.11% |
| D/E Ratio | 0.11 | 0.09 | 0.09 | 0.07 |
| Cash Flow | ||||
| Operating CF | ¥228,864M | ¥211,848M | ¥283,232M | ¥354,638M |
| Investing CF | -¥95,288M | -¥81,575M | -¥190,538M | -¥265,793M |
| Financing CF | -¥95,844M | -¥95,474M | -¥60,260M | -¥189,367M |
| Free CF | ¥115,712M | ¥104,061M | ¥168,559M | ¥225,276M |
| Efficiency | ||||
| ROE | 6.24% | 6.02% | 5.08% | 12.55% |
| ROA | 4.45% | 4.32% | 3.62% | 9.18% |
Latest IR Information
-
[Otsuka Holdings] Favorable Results in Phase 3 Trial of IgA Nephropathy Drug | June 2026
Otsuka Pharmaceutical's subsidiary has announced interim analysis results of the Phase 3 trial for the IgA nephropathy treatment drug cebepraelimab, demonstrating renal function preservation and progressing with approval application to the US FDA. There are no changes to the consolidated...
Read more -
Notice Regarding Share Buyback
Otsuka Holdings has decided to conduct a share buyback on June 2, 2026. The buyback period is from May 1, 2026, to May 31, 2026, with the total amount undisclosed. Details regarding the purpose and impact of the buyback are...
Read more -
Notice Regarding the Status of Treasury Stock Acquisition
Conducted treasury stock acquisition of 783,900 shares totaling 8,491,102,487 yen from April 1 to April 30, 2026.
Read more -
Consolidated Financial Summary for Q1 Fiscal Year Ending December 2026 [IFRS]
Consolidated revenue for Q1 of the fiscal year ending December 2026 was JPY 630,342 million (an 8.2% increase year-over-year), and net income attributable to owners of the parent for the quarter was JPY 98,348 million (a 15.7% increase year-over-year).
Read more -
Notice Regarding Completion of Payment for Disposal of Treasury Stock as Restricted Stock Compensation
On April 24, 2026, Otsuka Holdings disposed of 83,920 ordinary shares as restricted stock compensation at ¥11,090 per share, with a total amount of ¥930,672,800, and completed the payment procedures.
Read more
Latest News (5 items)
-
Average Analyst Rating: buy
Average Target Price: ¥12,608
Rating Score: 1.75 (Based on 12 analysts)
※1=Strong Buy, 5=Strong Sell
Company Information
About
Otsuka Holdings Co., Ltd. engages in the pharmaceuticals, nutraceuticals, consumer products, and other businesses worldwide. It develops pharmaceutical products in the fields of psychiatry, neurology, oncology, cardiovascular and renal system, autoimmune space digestive system, ophthalmology, and diagnostics, as well as intravenous solutions and medical devices. It also provides clinical testing, medical equipment and tools, food products, cosmetics, functional food products, chemical products, soft drinks, beverages, analytical and measurement equipment, nutritional products, vehicle headlight testers, synthetic resin molded products, paper products, quasi-drugs, household products, and packaging materials and electronic parts. In addition, it offers IT solutions; adhesive tapes; flaky titanate and compounds; infusion and clinical nutrition products; hydrazine; plant-based food products; reinsurance underwriting services; wine; stable isotopes; food supplements; software and services for management of mental healthcare systems; anticancer drugs; terracess; bio-pesticides; dietetic food products; spring and mineral water; and polyolefin foams. Further, it engages in the warehousing and transport, medical device operational management, shared service, environmental health management, and venture capital and incubation businesses; rental of medical devices and related products; purchase and sale of agricultural products; import and export trading business; tuberculosis research and development activities; rental of space and office businesses; manufacturing and development of xenotransplantation products; and processing and marketing of functional films, as well as planning, design, production, and construction of ceramic boards and arts, ceramic walls, reliefs, terracotta, ceramic OT and portraits, and ceramic sign boards; and operation of travel agency, and Hotel Ridge and California Table. The company was founded in 1921 and is headquartered in Chiyoda, Japan.